PQM130

CAS No. 2089415-51-8

PQM130( —— )

Catalog No. M26392 CAS No. 2089415-51-8

PQM130 is a Feruloyl-Donepezil Hybrid compound against the neurotoxicity induced by Aβ1-42 oligomer (AβO) and shows anti-inflammatory activity. PQM130 can be used in anti-AD studies.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 35 Get Quote
10MG 58 Get Quote
25MG 115 Get Quote
50MG 192 Get Quote
100MG 311 Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    PQM130
  • Note
    Research use only, not for human use.
  • Brief Description
    PQM130 is a Feruloyl-Donepezil Hybrid compound against the neurotoxicity induced by Aβ1-42 oligomer (AβO) and shows anti-inflammatory activity. PQM130 can be used in anti-AD studies.
  • Description
    PQM130 is a Feruloyl-Donepezil Hybrid compound against the neurotoxicity induced by Aβ1-42 oligomer (AβO) and shows anti-inflammatory activity. PQM130 can be used in anti-AD studies.(In Vitro):PQM130 had already shown anti-inflammatory activity in different in vivo models and neuroprotective activity in human neuronal cells. (In Vivo):The intracerebroventricular (i.c.v.) injection of AβO in mice caused the increase of memory impairment, oxidative stress, neurodegeneration, and neuroinflammation. Instead, PQM130 (0.5-1 mg/kg) treatment after the i.c.v. AβO injection reduced oxidative damage and neuroinflammation and induced cell survival and protein synthesis through the modulation of glycogen synthase kinase 3β (GSK3β) and extracellular signal-regulated kinases (ERK1/2). Moreover, PQM130 increased brain plasticity and protected mice against the decline in spatial cognition. PQM130 modulated different pathways compared to donepezil, and it is much more effective in counteracting AβO damage.
  • In Vitro
    ——
  • In Vivo
    PQM130 (0.5-1 mg/kg, i.p., daily for 10 days) treatment after the i.c.v. AβO injection reduces oxidative damage and neuroinflammation and induces cell survival and protein synthesis through the modulation of GSK3β and extracellular signal-regulated kinases (ERK1/2) . Animal Model:Adult male C57Bl/6 mice (9 weeks old, 25-30 g body weight) .Dosage:0.5 and 1.0 mg/kg.Administration:IP injection daily for 10 days.Result:Ameliorated Aβ1-42O-induced cognitive deficits in mice.Prevented Aβ1-42O-induced neuronal death in mice.Antagonized Aβ1-42O-Induced Oxidative Stress in Mice.Regulated GSK3β and ERK1/2 protein expressions in mice.Reduced Aβ1-42O-induced astrocytic activation in mice.
  • Synonyms
    ——
  • Pathway
    Membrane Transporter/Ion Channel
  • Target
    Beta Amyloid
  • Recptor
    ——
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2089415-51-8
  • Formula Weight
    381.472
  • Molecular Formula
    C23H27NO4
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 1.82 mg/mL (4.77 mM)
  • SMILES
    COc1cc(\C=C\C(=O)OCC2CCN(Cc3ccccc3)CC2)ccc1O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Süntar I, Küpeli Akkol E, Keles H, Yesilada E, Sarker SD, Arroo R, Baykal T. Efficacy of Daphne oleoides subsp. kurdica used for wound healing: identification of active compounds through bioassay guided isolation technique. J Ethnopharmacol. 2012 Jun 14;141(3):1058-70.
molnova catalog
related products
  • Chemerin-9 (149-157)

    The nonapeptide 149,YFPGQFAFS157 (chemerin-9), corresponding to the C terminus of processed chemerin, retained most of the activity of the full-size protein, with regard to agonism toward the chemerinR.the natural ligand of ChemR23 (chemerinR).

  • DSS30

    DSS30 is a P25/CDK5 inhibitor.DSS30 acts by inhibiting the phosphorylation of amyloid precursor protein cleaving enzyme 1 (BACEl), which reduces the secretion of β-amyloid (Aβ).

  • Buntanetap

    Buntanetap ((+)-Phenserine) is an orally active inhibitor of polyneurotoxic proteins (TINAPs) for the study of neurological disorders, endocrine and metabolic disorders, and cardiovascular diseases.